Efficacy and safety of ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis and DIPSS low/intermediate-1 risk myelofibrosis – the ROPEG-MF trial
Grant Data
Project Title
Efficacy and safety of ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis and DIPSS low/intermediate-1 risk myelofibrosis – the ROPEG-MF trial
Principal Investigator
Dr Singh, Gill Harinder Harry
(Principal Investigator (PI))
Co-Investigator(s)
Dr Sin Chun Fung
(Co-Investigator)
Dr Yim Rita Lok Hay
(Co-Investigator)
Dr Leung Man Kit Garret
(Co-Investigator)
Professor Kwong Yok Lam
(Co-Investigator)
Dr Yap Yat Hin Desmond
(Co-Investigator)
Duration
36
Start Date
2022-07-01
Amount
1189872
Conference Title
Efficacy and safety of ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis and DIPSS low/intermediate-1 risk myelofibrosis – the ROPEG-MF trial
Presentation Title
Keywords
low/intermediate-1, Myelofibrosis, Myeloproliferative neoplasm, pre-fibrotic, Ropeginterferon alfa-2b, the ROPEG-MF
Discipline
Others - Medicine, Dentistry and Health
HKU Project Code
09201046
Grant Type
Health and Medical Research Fund - Full Grant
Funding Year
2021
Status
On-going
Objectives
To determine the efficacy and safety of Ropeginterferon alfa-2b (ropeg) in patients with early or pre-fibrotic MF